A statistical method for estimating the no-observed-adverse-event-level
arXiv:2101.00427
Abstract
In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.
4 data examples, with raw data and R-code